{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:17:10Z","timestamp":1793348230770,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009886","name":"Regione Puglia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["201744BN5T_004"],"award-info":[{"award-number":["201744BN5T_004"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116353","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T20:07:07Z","timestamp":1710965227000},"page":"116353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Novel 6-alkyl-bridged 4-arylalkylpiperazin-1-yl derivatives of azepino[4,3-b]indol-1(2H)-one as potent BChE-selective inhibitors showing protective effects against neurodegenerative insults"],"prefix":"10.1016","volume":"270","author":[{"given":"Francesco","family":"Samarelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Purgatorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Lopopolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Deruvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Catto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Andresini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Nicolotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Valeria","family":"Miniero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4570-1981","authenticated-orcid":false,"given":"Modesto","family":"de Candia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo D.","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116353_bib1","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.ejmech.2024.116353_bib2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bmc.2014.12.057","article-title":"Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease","volume":"23","author":"Meena","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib3","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s12031-022-02009-7","article-title":"Recent advances towards diagnosis and therapeutic fingerprinting for Alzheimer's disease","volume":"72","author":"Pradhan","year":"2022","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2024.116353_bib4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2174\/1567205013666151116142302","article-title":"Non-pharmacological approaches to the prevention and treatment of Alzheimer's disease with respect to the rising treatment costs curr","volume":"13","author":"Klimova","year":"2016","journal-title":"Alz. Res."},{"key":"10.1016\/j.ejmech.2024.116353_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"A review on Alzheimer's disease pathophysiology and its management: an update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2024.116353_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2024.116353_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","article-title":"Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics","volume":"83","author":"Cummings","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116353_bib8","first-page":"321","article-title":"Cholinesterase inhibitors stabilize Alzheimer's disease, Ann. NY Acad","volume":"920","author":"Giacobini","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116353_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1586\/14737175.2015.990884","article-title":"Pharmacotherapy of Alzheimer's disease: current and future trends","volume":"15","author":"J Geldenhuys","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejmech.2024.116353_bib10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/ph15050545","article-title":"Unveiling the multitarget anti-alzheimer drug discovery landscape: a bibliometric analysis","volume":"15","author":"Sampietro","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2024.116353_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115169","article-title":"Thioxanthenone-based derivatives as multitarget therapeutic leads for Alzheimer's disease","volume":"250","author":"Tonelli","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib12","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1021\/ja020850+","article-title":"Fundamental reaction mechanism for cocaine hydrolysis in human butyrylcholinesterase","volume":"125","author":"Zhan","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116353_bib13","first-page":"1215","article-title":"Structure, activities and biomedical applications of human butyrylcholinesterase, Protein Pept","volume":"16","author":"Masson","year":"2009","journal-title":"Letture"},{"key":"10.1016\/j.ejmech.2024.116353_bib14","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer \u03b2-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.116353_bib15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/molecules23071544","article-title":"Insights into structure-activity relationships of 3-arylhydrazonoindolin-2-one derivatives for their multitarget activity on \u03b2-amyloid aggregation and neurotoxicity","volume":"23","author":"Purgatorio","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116353_bib16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1358\/dot.2004.40.8.850473","article-title":"Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease","volume":"40","author":"Geula","year":"2004","journal-title":"Drugs Today"},{"key":"10.1016\/j.ejmech.2024.116353_bib17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/NEN.0b013e31823cc7a6","article-title":"Butyrylcholinesterase is associated with \u03b2-amyloid plaques in the transgenic APPSWE\/PSEN1dE9 mouse model of Alzheimer disease","volume":"71","author":"Darvesh","year":"2012","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejmech.2024.116353_bib18","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.2174\/138161210793176536","article-title":"Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents","volume":"16","author":"Galdeano","year":"2010","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2024.116353_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tox.2006.11.069","article-title":"Sensitivity of butyrylcholinesterase knockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission","volume":"233","author":"Duysen","year":"2007","journal-title":"Toxicology"},{"key":"10.1016\/j.ejmech.2024.116353_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0197-0186(92)90189-X","article-title":"Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic developmentea study of molecular forms","volume":"21","author":"Arendt","year":"1992","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejmech.2024.116353_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.07.035","article-title":"Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-\u03b2 peptide in mice","volume":"225","author":"Furukawa-Hibi","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejmech.2024.116353_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.cbi.2016.04.022","article-title":"Reduced fibrillar \u03b2-amyloid in subcortical structures in a butyrylcholinesterase-knockout Alzheimer disease mouse model","volume":"259","author":"Darvesh","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2024.116353_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejmech.2017.03.062","article-title":"Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease","volume":"132","author":"Li","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/156720501301151207095006","article-title":"Butyrylcholinesterase as a diagnostic and therapeutic target for alzheimer's disease","volume":"13","author":"Darvesh","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejmech.2024.116353_bib25","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.3390\/ijms14035608","article-title":"Structure-based search for new inhibitors of cholinesterases","volume":"14","author":"Bajda","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116353_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1432-1033.1996.00036.x","article-title":"Asp70 in the peripheral anionic site of human butyrylcholinesterase","volume":"235","author":"Masson","year":"1996","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejmech.2024.116353_bib27","doi-asserted-by":"crossref","first-page":"41141","DOI":"10.1074\/jbc.M210241200","article-title":"Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products","volume":"278","author":"Nicolet","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/07391102.2014.896749","article-title":"Molecular docking of different inhibitors and activators to butyrylcholinesterase","volume":"33","author":"Chiou","year":"2014","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ejmech.2024.116353_bib29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/ml3001825","article-title":"Neuroprotective tri- and tetracyclic BChE inhibitors releasing reversible inhibitors upon carbamate transfer","volume":"3","author":"Darras","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116353_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib31","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/cmdc.201600161","article-title":"Multitarget drug discovery and polypharmacology","volume":"11","author":"Bolognesi","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116353_bib32","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1021\/jm3009458","article-title":"Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease","volume":"55","author":"Simoni","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib33","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1007\/s11064-014-1250-1","article-title":"Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces","volume":"39","author":"Rosini","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2024.116353_bib34","first-page":"17602","volume":"10","author":"Mishra","year":"2020","journal-title":"RCS Advance"},{"key":"10.1016\/j.ejmech.2024.116353_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejmech.2016.09.037","article-title":"New azepino[4,3-b]indole derivatives as nanomolar selective inhibitors of human butyrylcholinesterase showing protective effects against NMDA-induced neurotoxicity","volume":"125","author":"de Candia","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib36","article-title":"Radiosynthesis and whole-body distribution in mice of a 18 F-labeled azepino[4,3-b]indole-1-one derivative with multimodal activity for the treatment of Alzheimer's disease","author":"Lee","year":"2023","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2024.116353_bib37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejmech.2019.05.062","article-title":"Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease","volume":"177","author":"Purgatorio","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cmdc.202000583","article-title":"Evaluation of water-soluble mannich base prodrugs of 2,3,4,5-Tetrahydroazepino[4,3-b]indol-1(6H)-one as multitarget-directed agents for Alzheimer's disease","volume":"16","author":"Purgatorio","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116353_bib39","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejmech.2011.11.022","article-title":"New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds","volume":"47","author":"Faist","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103084","article-title":"Search for multifunctional agents against Alzheimer's disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives","volume":"90","author":"Jo\u0144czyk","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib41a","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ejmech.2014.05.066","article-title":"7-MEOTA-donepezil like compounds as cholinesterase inhibitors: synthesis, pharmacological evaluation, molecular modeling and QSAR studies","volume":"82","author":"Korabecny","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib41b","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1021\/acschemneuro.8b00024","article-title":"Novel multitarget-directed ligands aiming at symptoms and causes of Alzheimer's disease","volume":"9","author":"Wi\u0119ckowska","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2024.116353_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jnr.20025","article-title":"Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro","volume":"75","author":"Ono","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejmech.2024.116353_bib43","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1016\/j.bmc.2018.04.037","article-title":"Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment","volume":"26","author":"Liu","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib44","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2015.07.026","article-title":"Piperazine scaffold: a remarkable tool in generation of diverse pharmacological agents","volume":"102","author":"Shaquiquzzaman","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib45","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1734-1140(12)70878-2","article-title":"Effect of benzothiazole\/piperazine derivatives on intracerebroventricular streptozotocin-induced cognitive deficits","volume":"64","author":"Ozkay","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2024.116353_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116353_bib47","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/17460441.2010.520700","article-title":"Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs","volume":"5","author":"Zhang","year":"2010","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.116353_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2013.02.010","article-title":"Pharmacokinetics and the drug-target residence time concept","volume":"15\u201316","author":"Dahl","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2024.116353_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215291","article-title":"Comparative biophysical characterization: a screening tool for acetylcholinesterase inhibitors","volume":"14","author":"Patil","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116353_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jpba.2018.03.060","article-title":"Combination of human acetylcholinesterase and serum albumin sensing surfaces as highly informative analytical tool for inhibitor screening","volume":"155","author":"Fabini","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2024.116353_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1023\/B:JOPC.0000020081.36183.b8","article-title":"Partial purification and characterization of soluble isoform of butyrylcholinesterase from rat intestine","volume":"23","author":"Yildiz","year":"2004","journal-title":"Protein J."},{"key":"10.1016\/j.ejmech.2024.116353_bib52","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1111\/bph.13504","article-title":"Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding","volume":"173","author":"Vauquelin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116353_bib53","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1021\/acs.jmedchem.0c01863","article-title":"Kinetics-driven drug design strategy for next-generation acetylcholinesterase inhibitors to clinical candidate","volume":"64","author":"Zhou","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib54","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","article-title":"Sustainable drug discovery of multi-target-directed ligands for alzheimer's disease","volume":"64","author":"Rossi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib55","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/cells7100156","article-title":"The role of hydrogen peroxide in redox-dependent signaling: homeostatic and pathological responses in mammalian cells","volume":"7","author":"Di Marzo","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2024.116353_bib56","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1021\/jm5010754","article-title":"How a \u03b2-D-glucoside side chain enhances binding affinity to thrombin of inhibitors bearing 2-chlorothiophene as P1 moiety: crystallography, fragment deconstruction study, and evaluation of antithrombotic properties","volume":"57","author":"Belviso","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib57","unstructured":"Swiss Institute of Bioinformatics. http:\/\/www.swissadme.ch\/index.php (accessed 15 March 2024)."},{"key":"10.1016\/j.ejmech.2024.116353_bib58","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201600182","article-title":"A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules","volume":"11","author":"Daina","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.116353_bib59","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1021\/ci300367a","article-title":"AdmetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties","volume":"52","author":"Cheng","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2024.116353_bib60","series-title":"Open Babel: an Open Chemical Toolbox","author":"O'Boyle","year":"2011"},{"key":"10.1016\/j.ejmech.2024.116353_bib61","unstructured":"QUACPAC Package, Vers. 2.1.0.4, OpenEye Scientific Software, Santa Fe, NM.."},{"key":"10.1016\/j.ejmech.2024.116353_bib62","doi-asserted-by":"crossref","first-page":"D520","DOI":"10.1093\/nar\/gky949","article-title":"Protein Data Bank: the single global archive for 3D macromolecular structure data","volume":"47","author":"Burley","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2024.116353_bib63","series-title":"Schr\u00f6dinger Release 2023-1: BioLuminate","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116353_bib64","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1021\/ja00124a002","article-title":"A second generation force field for the simulation of proteins, nucleic acids, and organic molecules","volume":"117","author":"Cornell","year":"1995","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116353_bib65","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib66","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10822-019-00240-w","article-title":"Comparison of affinity ranking using AutoDock-GPU and MM-GBSA scores for BACE-1 inhibitors in the D3R Grand Challenge 4","volume":"33","author":"El Khoury","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2024.116353_bib67","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1021\/jm2005145","article-title":"A force field with discrete displaceable waters and desolvation entropy for hydrated ligand docking","volume":"55","author":"Forli","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib68","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/antiox11091631","article-title":"Novel phenothiazine\/donepezil-like hybrids endowed with antioxidant activity for a multi-target approach to the therapy of alzheimer's disease","volume":"11","author":"Carocci","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2024.116353_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115695","article-title":"Synthesis, computational and experimental pharmacological studies for (thio)ether-triazine 5-HT6R ligands with noticeable action on AChE\/BChE and chalcogen-dependent intrinsic activity in search for new class of drugs against Alzheimer's disease","volume":"259","author":"Czarnota-\u0141ydka","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116353_bib70","unstructured":"ROCS Package, Vers. 3.4.0.4, OpenEye Scientific Software, Santa Fe, NM.."},{"key":"10.1016\/j.ejmech.2024.116353_bib71","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.3390\/molecules26175208","article-title":"First-in-Class isonipecotamide-based thrombin and cholinesterase dual inhibitors with potential for alzheimer disease","volume":"26","author":"Purgatorio","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116353_bib72","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.3390\/molecules27134269","article-title":"Assessing the role of a malonamide linker in the design of potent dual inhibitors of factor Xa and cholinesterases","volume":"27","author":"Purgatorio","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116353_bib73","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1021\/acs.jmedchem.1c01784","article-title":"Probing fluorinated motifs onto dual AChE-MAO B inhibitors: rational design, synthesis, biological evaluation, and early-ADME studies","volume":"65","author":"Rullo","year":"2022","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T12:10:24Z","timestamp":1738411824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":74,"alternative-id":["S0223523424002332"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116353","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel 6-alkyl-bridged 4-arylalkylpiperazin-1-yl derivatives of azepino[4,3-b]indol-1(2H)-one as potent BChE-selective inhibitors showing protective effects against neurodegenerative insults","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116353"}}